Document Detail

Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
MedLine Citation:
PMID:  23225424     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Cholangiocarcinoma (CCC) is the second most common type of primary liver cancer, and is associated with a high rate of mortality due to the difficulty of early detection and resistance to chemotherapeutic agents. To evaluate the possibility for new therapeutic strategies, we examined the combined effect of gefitinib and gemcitabine on CCC.
MATERIALS AND METHODS: The effect of gefitinib, an inhibitor of epidermal growth factor receptor (EGFR) signaling, gemcitabine, which is a pyrimidine analog, and the combined effect of gefitinib and gemcitabine on CCC cells were evaluated both in vitro and in vivo.
RESULTS: EGFR mRNA expression and phosphorylation of EGFR were elevated in both human CCC cell lines studied, HuCCT1 and RBE, suggesting EGFR signaling is up-regulated in CCC cell lines. Gefitinib treatment at high concentration inhibited the proliferation of the CCC cell lines. Furthermore, gefitinib reduced the transforming growth factor alpha (TGFα)-induced proliferation of these cells. Gemcitabine also suppressed the growth of the CCC cell lines in a concentration-dependent manner. The combination of gefitinib and gemcitabine synergistically suppressed the growth of the CCC cell lines and induced greater apoptosis compared to the use of either agent alone. As a mechanism for this effect, we found less phosphorylation of the extracellular signal-regulated kinase (ERK) protein, which means the suppression of EGFR signaling, when these compounds were administered together. Cell transplantation assay dramatically demonstrated the synergistic effect of this combination on HuCCT1 xenografts in vivo.
CONCLUSION: The combination of gefitinib and gemcitabine inhibited the proliferation of CCC cells via induction of apoptosis. The combination of EGFR inhibitor and additional chemicals could be a new therapeutic approach for CCC.
Yoshimi Nakajima; Hitoshi Takagi; Satoru Kakizaki; Norio Horiguchi; Ken Sato; Noriaki Sunaga; Masatomo Mori
Related Documents :
23962454 - Cell-type-specific regulation of genes involved in testicular lipid metabolism: fatty a...
23634254 - Cdk4: a key player in the cell cycle, development, and cancer.
23661604 - Accumulation of micron sized iron oxide particles in endothelin-1 induced focal cortica...
24816924 - The antidepressant tranylcypromine alters cellular proliferation and migration in the a...
6300384 - Hormonal and cellular interactions in follicular steroid biosynthesis by the sheep ovary.
23974104 - High-throughput screen identifies disulfiram as a potential therapeutic for triple-nega...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  2013-05-02     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  5251-62     Citation Subset:  IM    
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma 371-8511, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Bile Duct Neoplasms / drug therapy*,  metabolism,  pathology
Bile Ducts, Intrahepatic / metabolism,  pathology
Carcinoma, Non-Small-Cell Lung / drug therapy,  metabolism,  pathology
Cell Growth Processes / drug effects
Cell Line, Tumor
Cholangiocarcinoma / drug therapy*,  metabolism,  pathology
Deoxycytidine / administration & dosage,  analogs & derivatives*,  pharmacology
Hep G2 Cells
Liver Neoplasms / drug therapy,  metabolism,  pathology
Lung Neoplasms / drug therapy,  metabolism,  pathology
Mice, Nude
Quinazolines / administration & dosage,  pharmacology*
Random Allocation
Receptor, Epidermal Growth Factor / metabolism
Signal Transduction / drug effects
Xenograft Model Antitumor Assays
Reg. No./Substance:
0/Quinazolines; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine; EC, Epidermal Growth Factor; S65743JHBS/gefitinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expression of E-Cadherin and ?-Catenin in T1 N0 Laryngeal Cancer.
Next Document:  Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo.